Cargando…
Pre-Existing Cross-Reactive Antibody Responses Do Not Significantly Impact Inactivated COVID-19 Vaccine-Induced Neutralization
Recent exposure to seasonal coronaviruses (sCoVs) may stimulate cross-reactive antibody responses against severe acute respiratory syndrome CoV 2 (SARS-CoV-2). However, previous studies have produced divergent results regarding protective or damaging immunity induced by prior sCoV exposure. It remai...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640209/ https://www.ncbi.nlm.nih.gov/pubmed/34868035 http://dx.doi.org/10.3389/fimmu.2021.772511 |
_version_ | 1784609293825212416 |
---|---|
author | Wang, Jin Guo, Cheng Cai, Lin Liao, Conghui Yi, Huaimin Li, Qianlin Hu, Huan Deng, Qiang Lu, Yuying Guo, Zhongmin Chen, Zeliang Lu, Jiahai |
author_facet | Wang, Jin Guo, Cheng Cai, Lin Liao, Conghui Yi, Huaimin Li, Qianlin Hu, Huan Deng, Qiang Lu, Yuying Guo, Zhongmin Chen, Zeliang Lu, Jiahai |
author_sort | Wang, Jin |
collection | PubMed |
description | Recent exposure to seasonal coronaviruses (sCoVs) may stimulate cross-reactive antibody responses against severe acute respiratory syndrome CoV 2 (SARS-CoV-2). However, previous studies have produced divergent results regarding protective or damaging immunity induced by prior sCoV exposure. It remains unknown whether pre-existing humoral immunity plays a role in vaccine-induced neutralization and antibody responses. In this study, we collected 36 paired sera samples from 36 healthy volunteers before and after immunization with inactivated whole-virion SARS-CoV-2 vaccines for COVID-19, and analyzed the distribution and intensity of pre-existing antibody responses at the epitope level pre-vaccination as well as the relationship between pre-existing sCoV immunity and vaccine-induced neutralization. We observed large amounts of pre-existing cross-reactive antibodies in the conserved regions among sCoVs, especially the S2 subunit. Excep t for a few peptides, the IgG and IgM fluorescence intensities against S, M and N peptides did not differ significantly between pre-vaccination and post-vaccination sera of vaccinees who developed a neutralization inhibition rate (%inhibition) <40 and %inhibition ≥40 after two doses of the COVID-19 vaccine. Participants with strong and weak pre-existing cross-reactive antibodies (strong pre-CRA; weak pre-CRA) had similar %inhibition pre-vaccination (10.9% ± 2.9% vs. 12.0% ± 2.2%, P=0.990) and post-vaccination (43.8% ± 25.1% vs. 44.6% ± 21.5%, P=0.997). Overall, the strong pre-CRA group did not show a significantly greater increase in antibody responses to the S protein linear peptides post-vaccination compared with the weak pre-CRA group. Therefore, we found no evidence for a significant impact of pre-existing antibody responses on inactivated vaccine-induced neutralization and antibody responses. Our research provides an important basis for inactivated SARS-CoV-2 vaccine use in the context of high sCoV seroprevalence. |
format | Online Article Text |
id | pubmed-8640209 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86402092021-12-04 Pre-Existing Cross-Reactive Antibody Responses Do Not Significantly Impact Inactivated COVID-19 Vaccine-Induced Neutralization Wang, Jin Guo, Cheng Cai, Lin Liao, Conghui Yi, Huaimin Li, Qianlin Hu, Huan Deng, Qiang Lu, Yuying Guo, Zhongmin Chen, Zeliang Lu, Jiahai Front Immunol Immunology Recent exposure to seasonal coronaviruses (sCoVs) may stimulate cross-reactive antibody responses against severe acute respiratory syndrome CoV 2 (SARS-CoV-2). However, previous studies have produced divergent results regarding protective or damaging immunity induced by prior sCoV exposure. It remains unknown whether pre-existing humoral immunity plays a role in vaccine-induced neutralization and antibody responses. In this study, we collected 36 paired sera samples from 36 healthy volunteers before and after immunization with inactivated whole-virion SARS-CoV-2 vaccines for COVID-19, and analyzed the distribution and intensity of pre-existing antibody responses at the epitope level pre-vaccination as well as the relationship between pre-existing sCoV immunity and vaccine-induced neutralization. We observed large amounts of pre-existing cross-reactive antibodies in the conserved regions among sCoVs, especially the S2 subunit. Excep t for a few peptides, the IgG and IgM fluorescence intensities against S, M and N peptides did not differ significantly between pre-vaccination and post-vaccination sera of vaccinees who developed a neutralization inhibition rate (%inhibition) <40 and %inhibition ≥40 after two doses of the COVID-19 vaccine. Participants with strong and weak pre-existing cross-reactive antibodies (strong pre-CRA; weak pre-CRA) had similar %inhibition pre-vaccination (10.9% ± 2.9% vs. 12.0% ± 2.2%, P=0.990) and post-vaccination (43.8% ± 25.1% vs. 44.6% ± 21.5%, P=0.997). Overall, the strong pre-CRA group did not show a significantly greater increase in antibody responses to the S protein linear peptides post-vaccination compared with the weak pre-CRA group. Therefore, we found no evidence for a significant impact of pre-existing antibody responses on inactivated vaccine-induced neutralization and antibody responses. Our research provides an important basis for inactivated SARS-CoV-2 vaccine use in the context of high sCoV seroprevalence. Frontiers Media S.A. 2021-11-19 /pmc/articles/PMC8640209/ /pubmed/34868035 http://dx.doi.org/10.3389/fimmu.2021.772511 Text en Copyright © 2021 Wang, Guo, Cai, Liao, Yi, Li, Hu, Deng, Lu, Guo, Chen and Lu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Wang, Jin Guo, Cheng Cai, Lin Liao, Conghui Yi, Huaimin Li, Qianlin Hu, Huan Deng, Qiang Lu, Yuying Guo, Zhongmin Chen, Zeliang Lu, Jiahai Pre-Existing Cross-Reactive Antibody Responses Do Not Significantly Impact Inactivated COVID-19 Vaccine-Induced Neutralization |
title | Pre-Existing Cross-Reactive Antibody Responses Do Not Significantly Impact Inactivated COVID-19 Vaccine-Induced Neutralization |
title_full | Pre-Existing Cross-Reactive Antibody Responses Do Not Significantly Impact Inactivated COVID-19 Vaccine-Induced Neutralization |
title_fullStr | Pre-Existing Cross-Reactive Antibody Responses Do Not Significantly Impact Inactivated COVID-19 Vaccine-Induced Neutralization |
title_full_unstemmed | Pre-Existing Cross-Reactive Antibody Responses Do Not Significantly Impact Inactivated COVID-19 Vaccine-Induced Neutralization |
title_short | Pre-Existing Cross-Reactive Antibody Responses Do Not Significantly Impact Inactivated COVID-19 Vaccine-Induced Neutralization |
title_sort | pre-existing cross-reactive antibody responses do not significantly impact inactivated covid-19 vaccine-induced neutralization |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640209/ https://www.ncbi.nlm.nih.gov/pubmed/34868035 http://dx.doi.org/10.3389/fimmu.2021.772511 |
work_keys_str_mv | AT wangjin preexistingcrossreactiveantibodyresponsesdonotsignificantlyimpactinactivatedcovid19vaccineinducedneutralization AT guocheng preexistingcrossreactiveantibodyresponsesdonotsignificantlyimpactinactivatedcovid19vaccineinducedneutralization AT cailin preexistingcrossreactiveantibodyresponsesdonotsignificantlyimpactinactivatedcovid19vaccineinducedneutralization AT liaoconghui preexistingcrossreactiveantibodyresponsesdonotsignificantlyimpactinactivatedcovid19vaccineinducedneutralization AT yihuaimin preexistingcrossreactiveantibodyresponsesdonotsignificantlyimpactinactivatedcovid19vaccineinducedneutralization AT liqianlin preexistingcrossreactiveantibodyresponsesdonotsignificantlyimpactinactivatedcovid19vaccineinducedneutralization AT huhuan preexistingcrossreactiveantibodyresponsesdonotsignificantlyimpactinactivatedcovid19vaccineinducedneutralization AT dengqiang preexistingcrossreactiveantibodyresponsesdonotsignificantlyimpactinactivatedcovid19vaccineinducedneutralization AT luyuying preexistingcrossreactiveantibodyresponsesdonotsignificantlyimpactinactivatedcovid19vaccineinducedneutralization AT guozhongmin preexistingcrossreactiveantibodyresponsesdonotsignificantlyimpactinactivatedcovid19vaccineinducedneutralization AT chenzeliang preexistingcrossreactiveantibodyresponsesdonotsignificantlyimpactinactivatedcovid19vaccineinducedneutralization AT lujiahai preexistingcrossreactiveantibodyresponsesdonotsignificantlyimpactinactivatedcovid19vaccineinducedneutralization |